How do you approach the treatment of patients with an e14a3 (b3a3) BCR-ABL fusion in chronic phase CML?  

The treatment is the same; the problem is how to monitor response as this rearrangement is detectable reliably by FISH and not by the typical RT-PCR. There is a report showing that CML with some rare fusion genes have a rapid response at early time points (3 and 6 months), but long term outcome seem...